1. Home
  2. HUBB vs BIIB Comparison

HUBB vs BIIB Comparison

Compare HUBB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hubbell Inc

HUBB

Hubbell Inc

HOLD

Current Price

$441.76

Market Cap

23.2B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$180.89

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBB
BIIB
Founded
1888
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
HUBB
BIIB
Price
$441.76
$180.89
Analyst Decision
Buy
Buy
Analyst Count
6
23
Target Price
$474.00
$176.48
AVG Volume (30 Days)
464.2K
1.9M
Earning Date
10-28-2025
10-30-2025
Dividend Yield
1.29%
N/A
EPS Growth
15.10
N/A
EPS
15.99
10.97
Revenue
$5,686,200,000.00
$10,065,900,000.00
Revenue This Year
$5.89
$3.61
Revenue Next Year
$7.65
N/A
P/E Ratio
$27.55
$16.52
Revenue Growth
0.82
4.77
52 Week Low
$299.43
$110.04
52 Week High
$484.26
$185.17

Technical Indicators

Market Signals
Indicator
HUBB
BIIB
Relative Strength Index (RSI) 55.71 70.85
Support Level $422.10 $174.53
Resistance Level $432.90 $183.15
Average True Range (ATR) 11.14 5.10
MACD 1.71 -0.03
Stochastic Oscillator 84.28 79.97

Price Performance

Historical Comparison
HUBB
BIIB

About HUBB Hubbell Inc

Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: